Exploring the Efficacy and Safety of Tislelizumab in Combination with S-1 in the Treatment of Patients with Postoperative Recurrent High-risk Intrahepatic CholangiocarcinomaA Prospective, Multicenter, Single-arm Phase II Clinical Study
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Tislelizumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 04 Nov 2024 New trial record